Product Program year 2020 Source: CMS Open Payments

Symfi Lo

Drug Infectious Disease

NDC 49502-425-93

Open in the dashboard

General payments

$7,805

399 payments

Research payments

$0

0 payments

Through program year 2020, $7,805 in general payments and $0 in research payments were reported against Symfi Lo (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $551 26
2019 General $7,254 373

Breakdown

Who paid General payments · program years 2019–2020
  1. Mylan Institutional Inc. $4,805 257 payments
  2. Mylan Pharmaceuticals Inc. $2,701 130 payments
  3. Mylan Specialty L.P. $299 12 payments
Top recipients General payments · program year 2020
  1. Jennifer Bartczak Internal Medicine · Wilton Manors, FL $41 7% · 2 payments
  2. Myron Davidson Internal Medicine · Wilton Manors, FL $41 7% · 2 payments
  3. Huy Ho San Diego, CA $41 7% · 1 payment
  4. Arvin Saluta Internal Medicine · San Diego, CA $41 7% · 1 payment
  5. Krisczar Bungay Internal Medicine · New York, NY $37 7% · 2 payments

The top 5 of 22 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Internal Medicine $274 54% · 11 practitioners
  2. Infectious Disease Internal Medicine $183 36% · 8 practitioners
  3. Adult Medicine Family Medicine $35 7% · 1 practitioner
  4. Family Medicine $19 4% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. Florida $272 49% · 10 recipients
  2. New York $103 19% · 5 recipients
  3. California $82 15% · 2 recipients
  4. Georgia $40 7% · 2 recipients
  5. North Carolina $24 4% · 1 recipient

The top 5 of 7 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

11

Prescriptions dispensed, refills included

Drug cost

$20,683

Paid at the pharmacy, in all

Prescribers

1

With 11 or more claims of it

Medicare Part D drugs matched to Symfi Lo, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Symfi Lo Efavirenz/Lamivu/Tenofov Disop Same name 1 11 $20,683

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

1 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
James Sunstrum Infectious Disease MI 11 $20,683 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

399 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record